Flerie AB Accelerates Growth: 54.7 M SEK Merger with Biosergen & TOL2 Trial Approval Boosts Value
Flerie AB’s merger with Biosergen AB boosts its biotech portfolio and capital, while its subsidiary’s TOL2 trial approval marks a new step toward revenue growth.
2 minutes to read